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Abstract 
Background & Aims: Activation of hepatic stellate cells (HSC) is a critical process involved in 
liver fibrosis. Several miRNAs are implicated in gene regulation during this process but their exact 
and respective contributions is still incompletely understood. Here we propose an integrative 
approach of miRNA-regulatory networks to predict new targets.
Methods: miRNA regulatory networks in activated HSCs were build using lists of validated 
miRNAs and the CyTargetLinker tool. The resulting graphs were filtered according to public 
transcriptomic data and the reduced graphs were analyzed through GO annotation. A miRNA 
network regulating the expression of TIMP3 was further studied in human liver samples, isolated 
hepatic cells and mouse model of liver fibrosis.  
Results: Within the up-regulated miRNAs, we identified a subnetwork of five miRNAs (miR-21-
5p, miR-222-3p, miR-221-3p miR-181b-5p and miR-17-5p) that target TIMP3. We demonstrated 
that TIMP3 expression is inversely associated with inflammatory activity and IL1-ß expression in 
vivo. We further showed that IL1-ß inhibits TIMP3 expression in HSC-derived LX-2 cells. Using 
data from The Cancer Genome Atlas (TCGA), we showed that, in hepatocellular carcinoma 
(HCC), TIMP3 expression is associated to survival (p<0.001), while miR-221 (p<0.05), miR-222 
(p<0.01) and miR-181b(p<0.01) are markers for a poor prognosis.  
Conclusions: Several miRNAs targeting TIMP3 are upregulated in activated HSCs and down-
regulation of TIMP3 expression is associated with inflammatory activity in liver fibrosis and poor 
prognosis in HCC. The regulatory network including specific miRNAs and TIMP3 is therefore 
central for the evolution of chronic liver disease.A
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Lay summary
Hepatic stellate cells (HSC) play a critical role in the progression of chronic liver diseases. Our 
study identified TIMP3 as a gene downregulated in activated HSCs and liver fibrosis, and further 
showed that TIMP3 is a marker of good prognosis in hepatocellular carcinoma. Measurement of 
TIMP3 expression could help diagnose the progression of liver disease.
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Introduction
Hepatic fibrosis is a dynamic and reversible process of scarring, which leads to excessive deposit 
of extracellular matrix (ECM) during most chronic liver diseases (CLDs) whatever the etiology 
including viral hepatitis, alcoholic liver cirrhosis and non-alcoholic fatty liver disease (NAFLD). 
Despite recent advances in antifibrotic therapies,1 CLDs account for 2 million deaths per year.2 
Understanding the complexity of the underlying molecular mechanisms remains an open challenge 
for developing new efficient therapies.
Hepatic stellate cells (HSCs) store vitamin A in normal liver but they are also critical players in 
liver fibrosis. Following injury, they undergo an activation process leading to myofibroblast-like 
phenotype characterized by proliferation, contractility, chemotaxis and fibrogenic properties.3 The 
molecular mechanisms that regulate HSC activation are driven by changes in microenvironment 
involving hepatocytes, inflammatory cells and the extracellular matrix (ECM). Such environment 
generates extracellular stimuli including growth factors and cytokines, cell-cell and cell-matrix 
interactions that modulate transcriptional gene expression. Epigenetic and post-transcriptional 
events are also critically involved and the role of microRNAs is now considered central in the 
regulation of liver fibrosis and HSC activation.4    
MicroRNA (miRNAs) are small non coding RNAs interacting with the 3’-untranslated region of 
mRNAs to promote their degradation and/or repress their translation.  40 miRNAs have been 
associated with fibrosis in several tissues, including liver, kidney, heart and lung, but more 
specific tissue signatures were also identified.5 In the liver, miRNAs and their potential use as 
biomarkers or therapeutic tools or targets  have been widely documented.6 Regulatory roles of 
miRNAs have been described in NAFLD,7 viral hepatitis,8,9 alcoholic liver diseases,10 cholestatic 
liver diseases11 and hepatocellular carcinomas.12 Pathways leading to fibrosis in CLDs are tightly 
regulated by miRNA–dependent mechanisms.13 However only 49 genes were reported as targets 
of down and up-regulated miRNAs in activated HSCs when compared to quiescent cells.4 The 
present study aimed to develop a whole-genome integrative approach based on miRNAs 
previously associated with HSC activation in order to identify new targets associated with liver 
fibrosis.  
Methods 
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Human Samples
Matching non-tumor liver samples were obtained from patients undergoing surgical hepatectomy 
for hepatocellular carcinoma (HCC). The patients were 7 women (mean age 61.8±8.6 years) and 
57 men (mean age 61.6±8.7 years). Etiology included chronic alcoholism, hepatitis B and C 
(supplementary table S1). Histological stages of fibrosis were graded according to the METAVIR 
score: F1, portal fibrosis without septa; F2, portal fibrosis with rare septa; F3, numerous septa 
without cirrhosis; and F4, cirrhosis. Necroinflammation activity (A) was graded as A0 (absent), 
A1 (mild), A2 (moderate) or A3 (severe). Liver samples were from the Biological Resources 
Center (BRC) at Rennes University Hospital. Access to this material was in agreement with 
French regulations and satisfied the requirements of the local Ethics Committee. 
Cell culture
Human hepatocytes and HSCs were isolated from histologically normal specimens of partial 
hepatectomies from patients undergoing hepatic resection for liver metastases as previously 
described.14  HSCs, LX-2 cell line and human Huh7D12 (Huh7) and HepG2 hepatoblastoma cell 
lines were maintained in Dulbecco’s minimal essential medium supplemented with 25 mM D-
Glucose, 4 mM L-Glutamine and 10% fetal bovine serum (FBS). LX-2 cells were serum starved 
for 24H before treatment with IL1- (3ng/ml) or TGF-  (5 ng/ml) for 24H in serum free medium. 
Mouse model of liver fibrosis 
Seven-week-old female C57Bl/6 mice were treated by intraperitoneal injection of CCl4 (Sigma-
Aldrich, St. Louis, MO, USA) diluted at 3% v/v in olive oil. Control mice were treated with the 
vehicle only (olive oil). For acute treatment, a single dose of 0.3 ml/kg of mouse weight was 
administered to mice. After 4h, 12h, 24h or 7 days, mice were sacrificed. Livers were collected, 
weighed and treated as previously described.15 Experiments performed on animals were approved 
by the local ethics committee (file number 17-1997) in accredited facilities (LA1610002) from the 
University of Liege.
In situ hybridizationA
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Formalin fixed, paraffin embedded (FFPE) tissue sections were deparaffinized with xylene 
(2x5min), rehydrated with decreasing concentrations of ethanol (100-60-30% for 2 minutes each), 
washed with distilled water and then dried for 10min at room temperature. Localization of mRNA 
expression in tissue samples was performed using the RNAscope® in situ hybridization (ISH) 
assay according to the manufacturer’s instructions (Advanced Cell Diagnostics Inc., Hayward, Ca, 
USA). We used RNAscope® mouse probes predesigned by the manufacturer for detection of Mm-
Timp3 in the second channel (probe mm-Timp3-C2, Cat No. 471311-C2), and of Mm-Acta2 in the 
first channel (probe Mm-Acta2-C1, Cat No. 319531). C2 and C1 signals were detected in red 
(FastRed) and green-blue respectively, using the RNAscope® 2.5 HD Duplex detection kit. Slides 
were counterstained with 25% hematoxylin and mounted with VectaMount™ Mounting Medium 
(Vector Laboratories, H-5000). 
RNA isolation and gene expression analysis by quantitative real-time PCR
Total RNA and miRNA were extracted either from cells or tissues using QIAzol Lysis Reagent 
(Cat No. 56302331) and miRNeasy Mini kit (Cat No. 217004) from Qiagen according to the 
manufacturer’s instructions. Reverse transcription was performed from 0.5 µg total RNA using 
Superscript II (Invitrogen). Real-time quantitative PCR was performed using the qPCR™ Core Kit 
for SYBR Green I® (EUROGENTEC™) and the ABI Prism 7700 real-time thermo-cycler 
(Perkin-Elmer, Foster city, CA, USA). Primer pairs for target genes are described in 
supplementary table S2. For miRNA 200 ng RNAs were reversed-transcribed using the 
miRCURY LNA miRNA PCR System (Qiagen). The primers were hsa-miR-21-5p (YP0020430), 
hsa-miR-222-3p (YP0020455), hsa-miR-221-3p (YP00204532), hsa-miR-181b-5p (YP00204530), 
hsa-miR-17-5p (YP02119304). and hsa-miR-29b-3p (YP00204679) (Qiagen).
Proteomic analyses of ECM from human fibrotic tissue samples 
Tissue samples from 18 adjacent non-tumor liver tissues were used for specific extracellular 
matrix (ECM) extraction. Tissue preparation and ECM protein enrichment were performed 
according to Dr Naba’s protocol.16 Briefly, tissue samples were mechanically homogenized and 
extracted sequentially using the CNMCS compartmental protein extraction kit (Millipore,Billerica, 
MA). Cytosolic, nuclear, membrane and cytoskeletal proteins were discarded and the final 
insoluble fraction enriched for ECM proteins was treated for spectrometry analyses. The ECM-A
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enriched samples were solubilized in urea, digested with PNGaseF, Lys-C, and trypsin. The 
resulting peptides were analyzed by LC-MS/MS on Orbitrap Fusion (Thermo Fisher Scientific, 
San Jose, CA). Mass spectra were interpreted with MaxQuant/Andromeda and MS/MS spectra 
were searched against the UniprotKB Homo sapiens (CP_Homo-Sapiens) database with fixed 
modification: carbamidomethyl(C), variable modifications: oxidation (M), oxidation (K), 
oxidation (P). Peptide identifications were filtered at 1% false discovery rate.  Protein digestion 
and mass spectrometry analyses were performed by the Proteomics Platform of the CHU de 
Québec Research Center (Quebec, Qc, Canada).
Bioinformatic Tools 
CyTargetLinker17 is a cytoscape plug-in for integrating regulatory interactions in network analysis. 
We used the Regulatory Interaction Networks (RegINs) provided on the CyTargetLinker website. 
RegINs describes networks containing miRNA regulatory interactions that are derived from online 
interaction databases. In the present study we selected miRTarBase (7.0) that contains MiRNA-
Target Interactions (MTIs) experimentally validated. MTIs are viewed as having strong support 
when they are validated by western blot, qPCR, or reporter assays. Gene annotations were made 
using Gene Ontology (GO) or DisGeNet, a discovery platform that contains a comprehensive 
catalogue of genes and variants associated to human diseases.
Statistical analyses
Experimental data are presented as box-and-whisker plots showing distribution of values from at 
least 3 independent experiments. Significant differences between groups were compared by Mann-
Whitney U (two groups) test or Kruskal-Wallis (more than two groups) test or Wilcoxon rank-sum 
test, when samples are apparied. Statistical calculations were performed with the R software, 
version 3.1.1. *P < 0.05, **P < 0.01 and ***P < 0.001 were considered significant.
Results
Building miRNA regulatory networks in activated hepatic stellate cellsA
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Based on the list of miRNA differentially expressed in activated HSCs (supplementary table S3), 
we searched for all target genes of up- and down-regulated miRNA. Using CyTargetLinker tool, 
8243 target genes were identified including 1215 targeted by only up-regulated miRNA, 4862 
targeted by only down-regulated miRNAs and 2166 targeted by both up-regulated and down-
regulated miRNA. In order to reduce the complexity of the graph, we selected miRNA-target 
interactions (MTI) that were previously experimentally validated according to the criteria from 
miRTarBase. A miRNA-target interaction is qualified as Strong if experimental evidences 
including qPCR, western-blot and/or Luciferase reporter assay support MTI. The reduced graph 
contained 825 target genes including 429 targets of only down-regulated miRNAs and 281 targets 
of only up-regulated miRNAs (Figure 1). The lists of genes are provided in supplementary table 
S4 and comparisons between lists are shown as Venn diagrams in supplementary figure S1. 
Among the resulting 825 genes, only 81 genes were annotated as liver fibrosis in the DisGeNET 
database (http://www.disgenet.org/).  
Among the 49 target genes experimentally validated in activated HSCs4 (supplementary table S3), 
37 were also found by CyTargetLinker using strong criteria, suggesting a good accuracy of the 
integrative approach (Figure 2). Among these genes, 24 and 11 are targets of down- or up-
regulated miRNAs, respectively, while 2 are targets of both up- and down-regulated miRNAs. In 
accordance with the dogma that activated HSCs are responsible for matrix remodeling, down-
regulated miRNAs led to up-regulation of matrix components (FN1, COL1A1, COL4A1, TNC) 
and inhibitor of matrix metalloprotease (TIMP2) while up-regulated miRNAs led to down 
regulation of matrix metalloproteinase (MMP2, MMP9). Similarly, decrease in SMAD7 and 
increase in both SMAD4 and TGFBR1 expression supported evidences for induced TGF-β 
signaling and activity in activated HSCs. 
In order to validate new target genes predicted by CyTargetLinker, we used transcriptomic data 
from genes differentially expressed in quiescent and culture-activated HSCs.18 For that purpose, 
we first selected genes showing two-fold changes (>2 and <0.5, for up- and down-regulated genes, 
respectively) and extracted miRNA-target interactions that matched between prediction and 
experiment. As shown in Figure 3A and 3B, 34 up-regulated genes and 17 down-regulated genes 
matched with genes predicted as targets of, respectively, down-regulated and up-regulated 
miRNAs in activated HSCs. We next focused on these reduced graphs for more in-depth analyzes.  
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Down-regulated miRNA networks correlate with extracellular matrix gene overexpression 
and cell proliferation
22 of the 34 identified up-regulated genes were associated with two major biological processes:  
extracellular structure organization (GO:0043062) and mitotic cell cycle process (GO:1903047) 
(supplementary table S5). In accordance with the role of miR29 family members as major 
regulators of fibrosis,13 mir29 down-regulation was associated with up-regulation of extracellular 
matrix genes including SPARC, COL5A1, COL3A1, COL1A1, LOX, LOXL2, TGFB2, ITGB1, 
DAG1 (Figure 3A). Similarly, IGF1 and LPL which are upregulated during HSC activation were 
recently identified as targets of mir29.19,20 Two other mir29 target genes, RNASEL and GPR85 
that have not been documented in liver fibrosis to date were also identified. RNASEL is an 
endoribonuclease implicated in the antiviral response and GPR85 is a member of the G protein-
coupled receptor (GPCR) family mainly associated with central nervous system disease. 
Beside the miR29-dependent regulatory networks, 8 miRNAs were associated with cell cycle 
genes (CCNE1, CDK6, CDKN3, CCNA2, CCNE1) and microtubule-regulatory genes (STMN1, 
KIF22 and AURKB) illustrating regulation of cell proliferation. In agreement with this, miR146a-
5p that targets KIF22, CDKN3 and CCNA2 inhibits HSC proliferation.21 Similarly miR155-5p 
targeting RAD51 attenuates HSC activation.22 Interestingly, the reduced graph enlightened the 
critical role of BIRC5 (alias survivin) which is controlled by four miRNAs (miR165-5p, miR-195-
5p, miR-150-5p, miR-355-5p). While the increased expression of BIRC5 was widely documented 
in chronic liver diseases and HCC,23 its regulation in HSCs remained poorly understood. Our 
study indicates that its increased expression is partly secondary to modifications affecting the 
abundance of a small number of miRNA.
Identification of a miRNA subnetwork targeting TIMP3
The up-regulated miRNA network was reduced to 9 miRNAs targeting 17 downregulated genes in 
activated HSCs (Figure 3B, supplementary table S5). Because TGFB1 signal is the driving force 
of liver fibrosis, it was not surprising to identify down regulation of antagonists of TGFB1 signal 
including the E3 ubiquitin ligase SMURF1 (responsible for TβRII ubiquitination and degradation 
in HSC24) and BMP-2 (antagonizing TGF-β1/ROCK-dependent fibrotic signaling25 and osteoblast 
differentiation26). Similarly,  TGFBR3 (alias betaglycan) a non-signaling receptor for TGF-β was 
downregulated during activation of HSCs.27 A
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The main intriguing observation was the targeting of the Tissue Inhibitor of Metalloproteinases 
(TIMP3) by five up-regulated miRNAs including miR-21-5p, miR-222-3p, miR-221-3p, miR-
181b-5p and miR-17-5p, thereby suggesting a strong negative regulation of TIMP3 in activated 
HSCs. To our knowledge, the regulation of TIMP3 by miRNAs was not documented in liver 
fibrosis and HSC to date. Based on literature meta-analysis we observed that miR-17-5p, miR-21-
5p, miR-181b-5p and the homologous miR-221/222-3p have already been implicated in the 
regulation of TIMP3 in other pathologies including cancer (Table 1).
 
TIMP3 expression is down-regulated in liver fibrosis 
In order to explore the regulation of TIMP3 in liver fibrosis, we first measured mRNA levels in 
adjacent non tumor liver tissues from the whole cohort of 64 patients with HCC. These samples 
encompass different stages of fibrosis (5 F1, 4 F2, 7 F3, 48 F4) and inflammatory activities (28 
A0, 17 A1, 16 A2, 3 A3). We observed a bell-shaped distribution of TIMP3 mRNA levels among 
fibrosis stages (Figure 4A). Remarkably, TIMP3 mRNA levels were significantly lower in liver 
fibrosis with highest inflammatory activities (Figure 4B).  Because TIMP3 is a secreted protein 
that binds to extracellular matrix,28 we used the  original approach developed by Naba et al16 to 
analyze its accumulation in ECM-enriched fraction of liver tissues from selected patients with 
fibrosis at different stages (5 F1, 3 F2, 4 F3 and 6 F4). As shown in Figure 4C, we observed a 
decrease (although not reaching statistical signification) in TIMP3 protein amounts associated 
with the highest fibrosis stages (p= 0.08225 between F1 and F4). 
To refine our understanding of the regulation of TIMP3 in liver fibrosis, we have 
investigated its expression in human hepatic cells in culture. TIMP3 was expressed in both in vitro 
activated human HSCs and the LX-2 cell line stimulated by TGF-β while cultured human 
hepatocytes and hepatocellular carcinoma cell lines (HepG2 and HuH7) expressed lower levels of 
TIMP3 (Figure 5A). These observations could appear as counterintuitive since we showed that 
miRNA network up-regulated in activated HSC is associated with TIMP3 down-regulation (Figure 
3B). However, HSCs activation is a complex phenomenon encompassing several phases and 
depending on the microenvironment.3 In agreement with the phenotypic heterogeneity of activated 
HSCs, cultured-HSCs transdifferentiate into fully mature myofibroblasts while the expression of 
profibrotic genes is still responsive to TGF-β in LX-2 cells. More recently, using single cell RNA 
sequencing approach, Krenkel et al29 described four sub-populations of activated myofibroblasts A
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(MFB) in CCl4-fibrotic livers (chronic treatment for three weeks) and further demonstrated that in 
vitro activation of HSC induced heterogeneity over time. 
Since TIMP3 expression was found to depend on the inflammatory context (Figure 4B), 
we investigated its expression in LX-2 cells stimulated by IL1- a cytokine produced by activated 
monocytes during inflammatory response. As shown in Figure 5B, IL1- diminished both TIMP3 
and TGF-β mRNA levels, while MMP9 expression, used as positive control, was induced as 
previously reported30. These observations are therefore consistent with LX-2 cells being in a 
transient state where gene expression can be modulated in response to both inflammatory 
cytokines and TGF-β. These responses are obviously disconnected from the complex response to 
liver injury that occurs in the whole tissue.
We therefore used a CCl4-induced acute liver failure model to investigate Timp3 mRNA levels 
during the first steps of liver response. Animals were sacrificed at 4-, 12-, 24- and 168-hours after 
CCl4 injection. At 24h, a decrease in Timp3 expression and a strong increase in IL1- were 
observed, which perfectly matches with our in vitro studies (Figure 6A).  To further explore the 
regulation of TIMP3 expression in liver fibrosis, we analyzed the expression of miR targeting 
Timp3 in the same samples. We observed that the expression of miR-17 (p=0.008), miR-181b 
(P=0.003), miR-222 (p=0.016) and miR-221 (P=0.055) was increased at 24h hour post-injection 
(Figure 6B). These observations suggest that inflammatory response induced by acute liver injury 
is associated with downregulation of Timp3 gene expression and upregulation of miRNAs 
targeting Timp3. 
Together our results have shown that five miRNAs upregulated in activated HSC are predicted to 
target TIMP3, suggesting the existence of a robust mechanism that tightly controls TIMP3 
expression. Following liver injury, inflammatory response is associated with HSCs activation and 
reduced TIMP3 expression as demonstrated by the inverse association of TIMP3 expression with 
inflammatory activity and IL1-ß expression. 
miR-21, miR-221 and miR-222 are markers of poor prognosis in hepatocellular carcinoma
Because TIMP3 expression was recently associated with a favorable survival in HCC,31 we 
hypothesized that miRNAs targeting TIMP3 might be inversely associated with survival.  Taking 
advantages of recent studies that integrate miRNA or mRNA expression data from independent 
sets of HCC32,33 we examined the prognostic value of miR-21, miR-222, mi-R221, miR-181b and A
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miR-17 expression. Using Kaplan-Meier Plotter tool (http://kmplot.com), we selected RNAseq 
data corresponding to the 379 HCC samples referred as Liver Hepatocellular Carcinoma (LIHC) 
in The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/).  miR-221, miR-
222 and miR-21 expressions are inversely associated with overall survival (Figure 7A), while 
miR-17 and miR-181b did not show significant association (data not shown). At the opposite, high 
TIMP3 expression in HCC samples from TCGA database is positively associated with survival. In 
accordance with the correlation between TIMP3 expression and favorable outcomes, we further 
showed that downregulation of TIMP3 in HCC is associated with tumor grade and gene signatures 
from HCC subtypes that include NCIP (The National Cancer Institute Proliferation subtype), 
SNUR (Seoul National University Recurrence subtype) and RS65, (65-gene risk score subtype) 
(Figure 7B).  To further investigate the correlation between TIMP3 expression and the miRNAs 
targeting TIMP3 in HCC samples, we selected 290 hepatocellular carcinoma (TCGA samples) 
corresponding to primary HCC tumors with both miRNA expression data33 and gene expression 
data (RNA-seq normalized read counts) in the “international cancer genome consortium” database 
(https://icgc.org). Next, we extracted miRNA expression data for these samples from Nagy’s 
study33 that integrated several HCC miRNa data sets including TCGA samples and we elaborated 
a new expression data set to study correlation between TIMP3 and miRs (supplementary table S6). 
Spearman's correlation analysis showed that the expression of miR-17 (ρ= -0.29, p=3.0 10-7), miR-
21(ρ= -0.25, p=1.6 10-5) and miR-222 (ρ= -0.20, p=5.0 10-4) was negatively correlated with that of 
TIMP3. The correlation of TIMP3 expression with miR-181b and miR-221 was negative but not 
significant (ρ= -0.1, p=0.09). Together these observation support evidence for the implication of 
miR-17, miR21, miR-181b, miR-221 and miR-222 in regulation of TIMP3 expression in chronic 
liver diseases. 
Discussion
On the basis of miRNA differentially expressed during activation of HSCs, we developed an 
integrative approach to identify new target genes and regulatory hubs. A major finding from this 
study was the miRNA subnetwork that targets TIMP3. Unlike other tissue inhibitors of 
metalloproteases, TIMP3 has been described as a tumor suppressor since decrease in TIMP3 
expression is associated with tumor aggressiveness and bad prognosis.34 Silencing of TIMP3 has 
been associated with promoter hypermethylation, loss of heterozygosity or miRNA-dependent 
regulation. In chronic liver disease, methylation status of TIMP3 is controverted since TIMP3 has A
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been found scarcely or not methylated in tumor, cirrhosis and chronic hepatitis,35 while other 
studies reported association of TIMP3 gene methylation with hepatocellular carcinoma.36 The 
regulation of TIMP3 expression by miRNAs has been reported in several pathologies (Table 1). 
However, there are no studies in liver fibrosis yet. Here, we showed that TIMP3 mRNA can be 
targeted by 5 miRNAs upregulated in in vitro activated HSCs, as compared to quiescent HSCs. In 
accordance with our study, miR-221-3p, miR-181b-5p and miR-222-3p are up-regulated in 
cirrhosis,37 miR-21 shows a 2-fold increase in HCV-dependent human fibrosis38 and miR-17-5P 
was identified as a serum biomarker for HCV-positive cirrhosis.39 Similarly TIMP3 is down-
regulated in livers from patients with nonalcoholic steatohepatitis and in HSCs treated with 
advanced glycation end-products which accumulate in patients with diabetes.40 Together these 
observations suggested that TIMP3 expression was down-regulated in liver fibrosis.
Using HCC RNAseq data from TCGA database, we further showed that TIMP3 expression was 
associated with overall survival while expression of miR-222, miR-221 and miR-21 predicted bad 
prognosis. The protective role of TIMP3 expression was also supported by its association with 
HCC subtypes characterized by low grade and low recurrence (Figure 7B). 
When searching in MiRTarBase that contains more than 38x104 interactions between 15064 
human genes and 2599 miRNAs, only TIMP3 and the tumor suppressor gene PTEN were 
commonly targeted by the five miRNAs miR-21-5p, miR-81-5p, miR222-3p, miR221-3p and 
miR17-5p (supplementary figure S2, supplementary table S7). In line with this common 
regulation, TIMP3 and PTEN were both implicated in miR-221/miR-222-mediated TRAIL 
resistance41 and miR-21-5p-mediated doxorubicin resistance.42 The critical role of PTEN in 
chronic liver diseases was recently demonstrated in vivo with Pten-null mice being more prone to 
develop progressive liver fibrosis and HSC activation than their wild type littermates.43 In 
addition, PTEN negatively correlates with liver fibrosis and activated HSCs in rat liver fibrosis.44 
Conversely, over-expression of PTEN inhibited HSCs activation and induced apoptosis.45 
TIMP3 deficiency was previously associated with inflammatory cells accumulation46 and 
exacerbated liver injury through enhanced inflammation and IL1-ß expression.47,48 Our 
observations have consistently shown that IL1-ß and TIMP3 expressions are inversely correlated 
in the mouse model of CCl4-induced acute liver injury. From a mechanistic point of view, TIMP3 
is the major inhibitor of ADAMs enzymes regulating the biodisponibility of cytokines and growth 
factors activity implicated in inflammatory response. Its decreased expression upon acute response A
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to liver injury might therefore contribute to the implementation of the inflammatory response 
required for activated HSCs-dependent tissue repair. As shown by in situ hybridization patterns 
(supplementary figure S3), diverse cell types expressed Timp3 with complex dynamics in both 
healthy and injured regions. The expression dynamics of Timp3 and miRNAs in whole liver are 
therefore not contributed by the sole hepatic stellate cells. Nevertheless, our observations indicate 
that IL1-ß inhibits TIMP3 expression in LX-2 cells raising the possibility that repression of this 
gene is part of an early response of HSCs to inflammation. We have also shown that TGF- 
induces TIMP3 expression and that IL1- downregulates TGF-ß expression, explaining how it 
affects also TIMP3 synthesis. A control of TIMP3 production by TGF- might therefore 
contribute to the  maintenance of immune homeostasis, in line with the anti-inflammatory role of 
TGF- in liver injuries.49  
Together our results demonstrate that TIMP3 expression can be regulated by miR-21-5p, miR-
181b-5p, miR-222-3p, miR-221-3p and miR-17-5p in activated HSC and that TIMP3 expression is 
inversely correlated to the expression of these miRs, and to the grade and inflammation activity of 
liver fibrosis. This regulation is associated with IL1--dependent immune response and future 
challenges will be to integrate the dynamic changes in miRNA networks to propose a model for 
TIMP3 gene regulation during the development of fibrosis.  
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Table 1: List of miRNAs previously associated with down-regulation of TIMP3 gene expression 
miRNA reference Physiopathologic context/effects
miR-21 present study Liver fibrosis/associated with activation of hepatic stellate cells
miR-221/222 present study Liver fibrosis/associated with activation of hepatic stellate cells
miR-181 present study Liver fibrosis/associated with activation of hepatic stellate cells
miR-17 present study Liver fibrosis/associated with activation of hepatic stellate cells
miR-17 (Yang et al., 2013) prostate tumor/induced growth and invasion
miR-21 miR-222 (Zhou et al., 2015) Peripheral nerve injury/inhibition of apoptosis
miR-21 (Chen et al., 2018) Gastric cancer/ increased chemoresistance
miR-21 (Gutsaeva et al., 2017) Ischemic retinopathies/ induced angiogenesis
miR-21 (Zhang et al., 2018l) Cervical Cancer/ increased cell proliferation, migration and invasion
miR-21 (Chen et al., 2017) Renal Cancer/increased cell proliferation and invasion
miR-21 (Hu et al., 2016) Spinal cord injury /pro-angiogenesis
miR-21 (Martin del Campo et al., 2015) Melanoma/increased cell invasion
miR-21 (Nagao et al., 2012) Pancreatic ductal adenocarcinoma/associated with poor survival
miR-21 (Song et al., 2010) Breast Cancer/induced cell  invasion
miR-92 (Liu et al., 2018) Atherosclerosis/ cell migration
miR-136 (Jin et al., 2017) Spinal cord ischemic injury/inhibition of apoptosis
miR-142 (Wu et al., 2018) Sciatic Nerve injury/inhibition of apoptosis
miR-181 (Heath et al., 2018) Calcific aortic valve disease/induced ECM degradation
miR-181 (Di Gregoli et al., 2017) Atherosclerosis/ induced ECM degradation
miR-181 (Zhou et al., 2016) Gastric cancer/ increase TGF-β-induced EMT
miR-181 (Panda et al., 2012) Endometrial cancer/
miR-181 (Wang et al., 2010a) hepatocarcinogenesis/induced cell survival, migration and invasion
miR-191 (Wang et al., 2018b) Prostate cancer/increased cell growth
miR-191 (Dong et al., 2015) endometriosis-associated ovarian cancer (EAOC)/ increased cell 
proliferation and invasionA
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miR-191 (Qin et al., 2014) Colorectal Cancer/ increased cell invasion 
miR-206 (Limana et al., 2011) HMGB1 injection in Chronically failing hearts/induced ECM degradation
miR-221&222 (Garofalo et al., 2009) Lung and liver cancer/induced chemoresistance
miR-221 (Diao et al., 2017) Papillary Thyroid Carcinoma/increased cell proliferation
miR-222 (Xu et al., 2017) Pulmonary artery hypertension / cell proliferation
miR-365 (Wang et al., 2018a) Diabetic retinopathies/ increased oxidative stress
miR-373 (Liu et al., 2016) Esophageal carcinoma/increased cell proliferation, migration and invasion
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Figure legends 
Figure 1. miRNA-genes regulatory interaction networks. The list of down-regulated and up-
regulated miRNA in activated hepatic stellate cells (supplementary table S3) was used as input for 
CyTargetLinker application. The resulting graphs illustrate the interactions between miRNA and 
genes. (A) Full graph including all target genes of down-regulated miRNA (blue) and up-regulated 
miRNA (red). (B) and (C) Graphs were reduced to interactions only supported by strong evidences 
as defined by CyTargetLinker application either for down-regulated miRNA network (B) or up-
regulated miRNA network (C). Target genes annotated by the term liver fibrosis in DisGeNet 
database (Disease id: C0239946) are shown in bold characters 
Figure 2. Comparison of genes targeted by up- and down-regulated miRNA in activated 
stellate cells. Genes identified by CyTargetLinker application with strong evidences criteria 
(green circle, n=825) were compared with target genes of up-(UP-HSC, n=17) and down-regulated 
miRNA (DOWN-HSC, n=35) previously reported in activated HSCs (supplementary table S3). 
Figure 3. miRNA-genes interaction networks of differentially expressed genes between 
quiescent and cultured HSCs. Genes differentially expressed during activation of HSCs from De 
Menicis’s et al 18 were used to filter miRNA-genes regulatory interaction networks (Figure 1). 
Resulting reduced networks are shown: (A) Up-regulated miRNA networks. (B) Down-regulated 
miRNA networks. 
Figure 4. TIMP3 expression in human liver fibrosis. (A) and (B) Boxplots showing mRNA 
levels of TIMP3 in liver biopsy samples with various (A) fibrosis stages (5 F1, 4 F2, 7F7 and 48 
F4) and (B) inflammatory activities (28 A0, 17 A1, 16 A2 and 3 A3). Statistical significance was 
calculated using the Wilcoxon rank-sum test. (C) TIMP3 protein levels in liver fibrosis. Specific 
extraction of extracellular matrix was performed according to Naba’s protocol16 and protein 
extracts were analyzed by mass spectrometry from human tissue samples at various fibrosis stages 
(5F1, 3F2, 4F3, 6F4). 
Figure 5. TIMP3 expression is down-regulated by IL1- in LX-2 cells. (A) Comparative 
analysis of TIMP3 expression in cultured hepatic cells. TIMP3 and ALB mRNA levels were A
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measured in activated HSC, LX-2 cell line treated or not with TGF-, primary human hepatocytes 
(HH), carcinoma cell lines (HuH7 and HepG2) as indicated. Bar plots show normalized levels 
relative to average TIMP3 levels in HSCs. (B) Box plots showing mRNA levels of TIMP3, TGF- 
and MMP9 expression in LX-2 cells treated by IL1- (three independent experiments). 
Figure 6. Timp3 and miR-17-5p miR-181b-5p miR-21-5p miR-221-3p miR-222-3p 
expression in CCl4-treated mice. Mice were treated by a single dose of CC4 (0.3 ml/kg of mouse 
weight) and were sacrificed 4-, 12-, 24- and 168-hours post-injection (A) Box plots show mRNA 
levels of Timp3 and IL1- expression. (B) Box plots show miR-17-5p, miR-21-5p, miR-181b-5p, 
miR-221-3p and miR-222-3p expression. 
Figure 7. TIMP3 expression is a marker for good prognosis of hepatocellular carcinoma. (A) 
Kaplan-Meier survival curves for TIMP3, miR-222, miR-221 and miR-21 expression. Clinical and 
expression data were extracted from TCGA_LIHC samples (n=364). (B) Box plots show TIMP3 
mRNA levels in different HCC grades and subtype from TCGA_LIHC primary HCC samples 
(n=294): histologic grades (Grades G1, G2 and G3), the Seoul National University recurrence 
subtype (SNUR, low and high recurrence), the 65-gene risk score subtype (RS65, low and high 
risk) and The National Cancer Institute proliferation subtype (NCIP, low and high proliferation). 
Statistical significance was calculated using the Wilcoxon rank-sum test (two groups) or the 
Kruskal-Wallis non-parametric test (more than two groups). HCC subtypes were extracted from50 . 
A
cc
ep
te
d 
A
rt
ic
le
A 
C 
B 
Figure 1 
liv_14476_f1.pptx
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
PTEN TGFB1 
ACTA2 
ACSL1 
HIF1AN 
CCN2 
TNC, SMO 
CD1A, FN1 
WNT5A, CTNNB1 
TIMP2, CTGF 
IGF1, TGFB2, WNT1, KLF11, SERPINH1, 
HDAC4, COL1A1, COL4A4, SP1, CCNE1, 
GRB2, PDGFA, TCF4, KLF6, P4HA1, 
CDKN1A, TGFBR1, AGTR1, SMAD4, 
VEGFA, KEAP1, SRF, PDGFC, MYB 
MMP2, PDCD4, CDKN1B, 
PPARG HNF4A, SPRY2, SMAD7, 
CHUK, SIRT1, JUN, MMP9 
Figure 2 
liv_14476_f2.pptx
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
A 
B 
Figure 3 
liv_14476_f3.pptx
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
 
Figure 4 
A 
B 
*** 
** 
* 
A0 A1 A2 A3 
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
 
C 
L
F
Q
 i
n
te
n
s
it
y
  
F1 F2 F3 F4 
F1 F2 F3 F4 
liv_14476_f4.pptx
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
H
S
C
 
L
X
2
 
L
X
2
 +
T
G
F
-β 
H
H
 
H
u
H
7
 
H
e
p
G
2
 
ALB 
1 
2 
3 
0 
3x105 
0 
TIMP3 
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
  
Figure 5 
A B 
2x105 
1x105 R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
  
TIMP3 
TGF-β 
MMP9 
- + 
IL1-β 
liv_14476_f5.pptx
This	article	is	protected	by	copyright.	All	rights	reserved
A
cc
ep
te
d 
A
rt
ic
le
p=0,016 
p=0,055 
p=0,008 
p=0,003 
p=0,003 
miR17 miR21 
miR181 miR221 
R
e
la
ti
v
e
 m
iR
N
A
 l
e
v
e
ls
 
miR222 
4 12 24 168 
A 
TIMP3 IL1-β 
Time (hours) after CCl4 injection 
* 
** 
* 
* 
* 
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
  
Time (hours) after CCl4 injection 
R
e
la
ti
v
e
 m
R
N
A
 l
e
v
e
ls
  
B 
Time (hours) after CCl4 injection 
Time (hours) after CCl4 injection 
Olive Oil 
CCL4 
Figure 6 
4 12 24 168 
4 12 24 168 4 12 24 168 
0.5 
1 
1.5 
2.5 
2.0 
12 
10 
8 
6 
4 
2 
0 
0.5 
1.0 
1.5 
2.0 
0 
0.5 
1.0 
1.5 
2.0 
0 
0.5 
1.0 
1.5 
2.0 
0 
0.5 
1.0 
1.5 
2.0 
0 
0.5 
1.5 
2.5 
3.5 
liv_14476_f6.pptx
A
cc
ep
te
d 
A
rt
ic
le
Figure 7 
A 
B 
TIMP3 
High Low High Low 
liv_14476_f7.pptx
A
cc
ep
te
d 
A
rt
ic
le
